S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Laser breakthrough could send stock soaring 2,467% (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Laser breakthrough could send stock soaring 2,467% (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Laser breakthrough could send stock soaring 2,467% (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
Laser breakthrough could send stock soaring 2,467% (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
LON:VAL

ValiRx (VAL) Share Forecast, Price & News

GBX 9
+0.25 (+2.86%)
(As of 06/9/2023 ET)
Compare
Today's Range
8.50
9.25
50-Day Range
8.75
11.09
52-Week Range
8.50
24.96
Volume
300,165 shs
Average Volume
528,558 shs
Market Capitalization
£9.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VAL stock logo

About ValiRx (LON:VAL) Stock

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

VAL Stock News Headlines

Get MarketBeat All Access Free for 30 Days
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Try it free for 30 days.
Self Storage Gr Share Chat
Get MarketBeat All Access Free for 30 Days
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Try it free for 30 days.
ValiRx plc (EAJF.F)
See More Headlines

VAL Price History

VAL Company Calendar

Last Earnings
9/07/2020
Today
6/10/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
£-1,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.14 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£9.21 million
Optionable
Not Optionable
Beta
1.48

Key Executives

  • Dr. Suzanne J. Dilly B.Sc. (Age 44)
    BSc, Ph.D., CEO & Director
    Comp: $159.18k
  • Mr. James Gerry Desler FCA (Age 66)
    CFO & Exec. Director
    Comp: $48k
  • Mr. Kumar Nawani
    Head of Operations
  • Dr. Catherine Jane Tralau-Stewart Ph.D.
    Chief Scientific Officer
  • Mr. Tarquin Edwards
    Head of Investor Relations & Communications
  • Mr. Mark Treharne
    Corp. Devel. Mang.













VAL Stock - Frequently Asked Questions

How have VAL shares performed in 2023?

ValiRx's stock was trading at GBX 14 at the beginning of 2023. Since then, VAL shares have decreased by 35.7% and is now trading at GBX 9.
View the best growth stocks for 2023 here
.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) issued its quarterly earnings results on Monday, September, 7th. The company reported ($4.43) EPS for the quarter.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 9.

How much money does ValiRx make?

ValiRx (LON:VAL) has a market capitalization of £9.21 million. The company earns £-1,770,000.00 in net income (profit) each year or GBX (0.03) on an earnings per share basis.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The official website for the company is www.valirx.com. The company can be reached via phone at +44-20-30084416.

This page (LON:VAL) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -